Over the last 2 decades, significant progress has been made in our understanding of the genomics, tumor immune microenvironment, and immunogenicity of malignant melanoma. Historically, the prognosis ...
In a report released today, Reni Benjamin from JMP Securities reiterated a Hold rating on Instil Bio (TIL – Research Report). The ...
An expert explained how a patient’s own T cells can be extracted, manufactured and infused back into the body as a treatment ...
Research and development (R&D) expenses: R&D expenses for the three months ended September 30, 2024, were $14.4 million, compared to $14.2 million for the same period in 2023. The increase was due ...
Two cycles of dual neoadjuvant immunotherapy (nivolumab/ipilimumab or nivolumab/relatlimab) induced high pathological ...
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible through seamless ...
SAN CARLOS, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel ...
Results of a study recently published in the journal JCO Precision Oncology show that in the clinical trial context, combined ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback